On August 9, 2024, Shanghai ChemPartner Co., Ltd (ChemPartner) and the Hong Kong Polytechnic University (PolyU) marked the signing of a Memorandum of Understanding (MOU). The MOU was signed by Professor Larry Ming Cheung Chow, Head of the Department of Applied Biology and Chemical Technology at PolyU, and Mr. Shixin Fan, Director of Shanghai ChemPartner Co., Ltd. Mr. William WOO, Chairman and CEO of ChemPartner, attended the ceremony as well.
ChemPartner is a leader in innovative drug development and manufacturing. The company is committed to advancing pharmaceutical science through relentless innovation and boasts a premier team of ADC drug researchers. ChemPartner offers comprehensive services from antibody development to IND application.
With a 15-year history of excellence, ChemPartner’s one-stop ADC R&D platform has supported hundreds of early-stage ADC projects for clients, securing patents for innovative products. The seasoned chemical team has collaborated on ADC projects for over 20 different targets and has designed and synthesized more than 1000 linker-payload compounds, including both toxic and non-toxic varieties. The company’s extensive technical expertise and industry acumen span new drug development, biotechnology, and beyond.
This collaboration between ChemPartner and the Department of Applied Biology and Chemical Technology at PolyU will delve into the pharmaceutical sciences, with a particular focus on the development of novel immunotherapies and conjugated drugs. The long-term goal is to benefit cancer patients. By pooling their strengths, the partnership aims to bridge the gap from foundational research to therapeutic drug development, thereby accelerating the innovation and commercialization of groundbreaking cancer treatments. This synergy not only fosters the exchange of knowledge and resources but also paves the way for significant advancements in oncology.
During the ceremony, Mr. William Woo, Chairman and CEO of ChemPartner, stressed the significance of this collaboration, saying, “Our cooperation with the Hong Kong Polytechnic University is a major event for ChemPartner. We hope that through this partnership, we can promote exchanges and collaboration between the two sides in the field of medical technology, share resources, and leverage each other’s strengths, to jointly make greater contributions to human health.”
Professor Ming Cheung Chow also expressed his excitement about the collaboration, stating, “This partnership exemplifies the need for academia and industry to work closely together to achieve success. To create a win-win situation, we will focus on the early discovery phase of markers, while ChemPartner will work on the later stages of antibody development.”
This collaboration is a platform for mutual prosperity and invigorates the pharmaceutical technology sector with fresh impetus. This alliance between ChemPartner and PolyU is poised to yield a variety of impactful outcomes to enhanced health and well-being worldwide.
